Brand Name

Krystexxa

Generic Name
Pegloticase
View Brand Information
FDA approval date: September 14, 2010
Classification: Uric Acid-specific Enzyme
Form: Injection

What is Krystexxa (Pegloticase)?

KRYSTEXXA ® is indicated, for the treatment of chronic gout in adult patients refractory to conventional therapy. Gout refractory to conventional therapy occurs in patients who have failed to normalize serum uric acid and whose signs and symptoms are inadequately controlled with xanthine oxidase inhibitors at the maximum medically appropriate dose or for whom these drugs are contraindicated. KRYSTEXXA ® is a PEGylated uric acid specific enzyme indicated for the treatment of chronic gout in adult patients refractory to conventional therapy. Limitations of Use: KRYSTEXXA is not recommended for the treatment of asymptomatic hyperuricemia. Limitations of Use: KRYSTEXXA is not recommended for the treatment of asymptomatic hyperuricemia.

Approved To Treat

Top Global Experts

Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms

Related Clinical Trials

A Phase 3, Multicenter, Double-blind, Randomized Controlled Study Evaluating the Efficacy and Safety of Pegloticase Administered by Subcutaneous Injection Compared With Pegloticase Administered by Intravenous Injection, Both Administered Concurrently With Methotrexate Weekly, in Participants With Uncontrolled Gout
A Phase 3, Multicenter, Double-blind, Randomized Controlled Study Evaluating the Efficacy and Safety of Pegloticase Administered by Subcutaneous Injection Compared With Pegloticase Administered by Intravenous Injection, Both Administered Concurrently With Methotrexate Weekly, in Participants With Uncontrolled Gout
Enrollment Status: Recruiting
Publish Date: March 31, 2026
Intervention Type: Drug
Study Phase: Phase 3

Summary: The primary objective of this trial is to evaluate the effect of pegloticase 18 mg subcutaneously (SC) every two weeks with methotrexate (MTX) versus pegloticase 8 mg intravenously (IV) every two weeks with MTX on the response rate during Month 6, as measured by the sustained normalization of serum uric acid (sUA) to \< 6 mg/dL for at least 80% of the time during Month 6.

A Phase 2, Multicenter, Open-label, Efficacy and Safety Study of AR882 and XOI Co-administration in Participants With Uncontrolled Gout Who Have Previously Failed Uricase Treatment
A Phase 2, Multicenter, Open-label, Efficacy and Safety Study of AR882 and XOI Co-administration in Participants With Uncontrolled Gout Who Have Previously Failed Uricase Treatment
Enrollment Status: Recruiting
Publish Date: March 02, 2026
Intervention Type: Drug
Study Phase: Phase 2

Summary: This study will assess the effect of AR882 and XOI co-administration on sUA lowering as well as reducing tophus burden in the population that has failed uricase treatment (eg., pegloticase). Failed uricase treatment is defined as having an inherent intolerance, anaphylaxis, infusion reaction, antibody development, and/or at least one sUA level that rose to greater than 6 mg/dL while on therapy.

View All Clinical Trials

Related Latest Advances

Plain language summary: gout remission with pegloticase.
Plain language summary: gout remission with pegloticase.
Journal: Therapeutic advances in musculoskeletal disease
Published: January 05, 2026
Biological Therapies for Urate Lowering and Inflammation Control in Gout Management.
Biological Therapies for Urate Lowering and Inflammation Control in Gout Management.
Journal: Journal of inflammation research
Published: December 31, 2025
Research progress on multidimensional intervention strategies for hyperuricemia: Western medicine, Traditional Chinese Medicine, and emerging therapies.
Research progress on multidimensional intervention strategies for hyperuricemia: Western medicine, Traditional Chinese Medicine, and emerging therapies.
Journal: Frontiers in endocrinology
Published: October 10, 2025
View All Latest Advances